Mirouse A, Barete S, Desbois AC, et al. - Through a multicenter, prospective, open-label study of 30 individuals who fulfilled the criteria of the International Study Group for Behçet disease (BD) and who were diagnosed as having active oral ulcers resistant to colchicine, experts examined the long-term safety and efficiency of ustekinumab therapy for BD-related oral ulcers. At weeks 12 and 24, complete response was achieved in 60.0% and 88.9% of individuals, respectively. The median Behçet Syndrome Activity Score at weeks 12 and 24 vs baseline was significantly lesser. Twenty-six individuals were still receiving ustekinumab treatment following a median follow-up of 12 months. BD flare (n = 3) and side effects (n = 1) were causes of ustekinumab discontinuation. Seven individuals had adverse events, including headaches (n = 4) and asthenia (n = 2), with no dangerous side effects. Hence, in treating BD-related oral ulcers that are resistant to treatment with colchicine, ustekinumab appeared to be efficient.